Our mission

Exploit discoveries in the prostate cancer biomarker field to develop assays enabling definitive diagnosis and prognosis on the patient's FIRST prostate biopsy.

Our vision

Develop diagnostic and prognostic tests for prostate cancer, providing both patients and physicians with critical information for informed treatment choices.

Our story

Proveri was founded in 2004 by Dan Mercola, M.D. and Michael McClelland, Ph.D on the research results of a $14 million study funded by the National Cancer Institute. Proveri licensed the proprietary technology of the NCI funded research to develop diagnostic and prognostic tests for patients with newly suspected prostate cancer.

Milestones & Accomplishments

•

Validated gene expression signatures provide basis for the development of accurate diagnosis of prostate cancer and prognosis of outcome for cancer patients.

•

Technology enables accurate diagnosis on biopsies termed "equivocal" in combination with traditional (H&E staining) histological analysis.

•

Diagnostic and prognostic prostate cancer detection technology serves a significant unmet medical need in a large and expanding market and will produce health and economic savings by providing for more informed treatment options.